CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal ...

In the international, multi-centre trial, the Evolut TAVR demonstrated “continued superior” valve performance, according to ...

Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years ...

holding more than 60% of the US TAVR market. But change may be afoot. Medtronic recently released two-year results from a clinical trial comparing its Evolut system to Edwards’ SAPIEN ...

On Sunday, Medtronic published five-year data from a low-risk clinical trial of its Evolut transcatheter aortic valve replacement (TAVR) system. In the trial, TAVR, which assists patients ...

Dr. George and the Columbia Valve team discussed new technology from the two largest structural heart companies, the Edwards SAPIEN X4 and the Medtronic Evolut FX. Receive the the latest news, ...

That said, patients aged 65-69 who underwent early TAVR derived the most benefits, with significant reduction in stroke risk (0% early TAVR vs. 13% CS) and had six times lower rate of death ...

Furthermore, the launch and European release of the Evolut TAVR system in mid-2020 demonstrated Medtronic’s continued commitment to innovation. The company's consistent dividend payouts bolstered ...